Eradicating tumor drug resistance at its YAP-biomechanical roots

EMBO Journal

Volumn 35, Issue 5, 2016, Pages 459-461

  Zanconato, Francesca ^a   Piccolo, Stefano ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAZ; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG; B RAF KINASE; INDOLE DERIVATIVE; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULFONAMIDE;

CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; CELL VIABILITY; CYTOSKELETON; DRUG EFFICACY; DRUG EXPOSURE; EXTRACELLULAR MATRIX; GENETIC RESISTANCE; IMMUNE SYSTEM; IN VITRO STUDY; MECHANOTRANSDUCTION; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; HUMAN; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MELANOMA; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TRANSCRIPTION FACTORS;

EID: 84959366859     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.15252/embj.201593584     Document Type: Short Survey

References (9)

1. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S, Piccolo S, (2013) A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154: 1047-1059
2. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S, (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147: 759-772
3. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S, (2011) Role of YAP/TAZ in mechanotransduction. Nature 474: 179-183
4. Fedorenko IV, Gibney GT, Sondak VK, Smalley KS, (2015) Beyond BRAF: where next for melanoma therapy? Br J Cancer 112: 217-226
5. Flaherty KT, Hodi FS, Fisher DE, (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12: 349-361
6. Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E, (2015) Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell 27: 574-588
7. Kim MH, Kim J, Hong H, Lee S-H, Lee J-K, Jung E, Kim J, (2016) Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J 35: 462-478
8. Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, LaBarge MA, (2015a) Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Mol Biol Cell 26: 3946-3953
9. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, et al, (2015b) The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47: 250-256